Press Releases Year None202020192018201720162015201420132012201120102009 11/23/20 Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December 11/05/20 Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update 11/02/20 Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November 10/27/20 Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan 10/26/20 Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors 10/22/20 Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020 10/19/20 U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma 10/09/20 Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor 10/09/20 Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor 09/21/20 Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab 09/19/20 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial 09/15/20 Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors 09/14/20 Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020 09/08/20 Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September 09/08/20 Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer 09/08/20 Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology 08/24/20 Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell Carcinoma 08/06/20 Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update 07/29/20 Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020 07/20/20 Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma 06/30/20 Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer 06/18/20 Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020 06/11/20 Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer 06/03/20 Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June 05/13/20 Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types 05/06/20 Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May 05/05/20 Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update 04/21/20 Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020 04/20/20 Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma 04/08/20 Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020 03/25/20 Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma 03/02/20 Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors 02/26/20 Exelixis Announces Webcasts of Investor Conference Presentations in March 02/25/20 Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer 02/25/20 Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update 02/12/20 Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020 02/10/20 Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer 02/06/20 Exelixis Announces Webcasts of Investor Conference Presentations in February 01/29/20 Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma 01/24/20 Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma 01/12/20 Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance 01/07/20 Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 01/07/20 Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors
